4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Binge Eating Disorder by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 19 ongoing clinical trials involving Binge Eating Disorder
Of the 19 trials,5 trials are in Phase II/III
Furthermore, 4 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Binge Eating Disorder by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Binge Eating Disorder, aCentral Nervous Systemcondition.North America and Asia Pacific regions are involved in Binge Eating Disorder-related drug trials.

Yale University: The leading ongoing Binge Eating Disorder related clinical trial sponsor

Yale Universityis the top sponsor for Binge Eating Disorder-related ongoing clinical trials.

The Children's Mercy Hospital, Oklahoma State University Center for Health Sciences, Idorsia Pharmaceutical Ltd, and University of Sydneyare a few other notable clinical trial sponsors involving Binge Eating Disorder. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Binge Eating Disorder

Lisdexamfetaminedimesylate (Elvanse/ Vyvanse/ Venvanse/ Aduvanz), and Fluoxetine hydrochloride (Sarafem, Prozac, Elindra, Fontex, Fluctin, Fluoxetine, Reneuron, Adofen, Fluctine) are among the key marketed drugs involving Binge Eating Disorder.

Lisdexamfetaminedimesylate (Elvanse/ Vyvanse/ Venvanse/ Aduvanz) is a psychostimulant agent. It functions via Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3) Inhibitor; Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Inhibitor mechanism of action. Lisdexamfetaminedimesylate is formulated as hard gelatin capsules and chewable tablets for oral route of administration. It is marketed for the treatment of Binge Eating Disorder, and Attention Deficit Hyperactivity Disorder (ADHD).Lisdexamfetaminedimesylatewas first approved in 2007 and is marketed globally including the US, the UK, Australia, Germany, and Japan by Takeda Pharmaceutical Co Ltd, Shire Pharmaceuticals Ireland Ltd, OpoPharma Vertriebs AG. and several other companies.

Fluoxetine hydrochloride (Sarafem, Prozac, Elindra, Fontex, Fluctin, Fluoxetine, Reneuron, Adofen, Fluctine) is an anti-depressive agent. It functions via Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4) Inhibitor mechanism of action.  It is formulated as hard gelatin capsules, tablets and solution for oral route of administration. Fluoxetine hydrochloride is marketed for the treatment of Binge Eating Disorder, and several other indications including Anxiety Disorders, Depression, Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorders, Anorexia Nervosa, Bulimia Nervosa, Premenstrual Dysphoric Disorder (PMDD), Premenstrual Syndrome. It was first approved in 1986 and is marketed globally including the US, the UK, Australia, and Germanyby Eli Lilly and Co.